January 22, 2018 4:14 PM ET


Company Overview of X-Chem, Inc.

Company Overview

X-Chem, Inc. operates independently of Pharmaceutical Product Development, LLC as of January 06, 2016.

100 Beaver Street Suite 101

Waltham, MA 02453

United States





Key Executives for X-Chem, Inc.

X-Chem, Inc. does not have any Key Executives recorded.

X-Chem, Inc. Key Developments

X-Chem Enters Expanded Global Drug Discovery and Technology Transfer Collaboration with Astrazeneca

X-Chem, Inc. announced a significant expansion of their existing global drug discovery collaboration with the global biopharmaceutical company AstraZeneca. The new agreement focuses on the synthesis and delivery of custom libraries to AstraZeneca as well as the transfer of the DEX platform, allowing for in-house screening of DNA-encoded libraries at AstraZeneca. It is the third agreement between AstraZeneca and X-Chem since 2012 and builds on the success of the parties’ existing collaboration, which has resulted in numerous licenses to novel small molecules across multiple discovery programs and therapeutic indications to date. Under the terms of the agreement, X-Chem will receive upfront technology access and license fees, as well as multi-year committed funding. X-Chem is also eligible for additional payments linked to the exercise of specific technology transfer options and the achievement of certain R&D and commercial milestones. In addition, X-Chem will receive royalties for each successfully commercialized drug that results from joint target-based collaboration programs.

X-Chem, Inc. Presents at BIO One-on-One Partnering™, Jan-07-2018

X-Chem, Inc. Presents at BIO One-on-One Partnering™, Jan-07-2018 . Venue: San Francisco, California, United States.

X-Chem, Inc. and Abilita Bio, Inc Announces a Joint Research Collaboration

X-Chem, Inc. and Abilita Bio, Inc. announced a joint research collaboration that will leverage the synergy between each company's platform technology to enable the discovery of novel modulators of high-value G-protein coupled receptors (GPCR) and ion channel targets. Under the terms of the agreement, Abilita will generate EMPsTM for several high-value GPCR and ion-channel targets, which will be screened by X-Chem using its proprietary DEXTM libraries to identify agonists and/or antagonists, as dictated by the target biology and desired mechanism of action. The most promising drug leads resulting from these activities will be selected for further development and commercialization by the parties.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact X-Chem, Inc., please visit www.x-chemrx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.